uniQure NV (LTS:0EE0)
$ 16.2348 0.9948 (6.53%) Market Cap: 762.83 Mil Enterprise Value: 395.19 Mil PE Ratio: 0 PB Ratio: 14.23 GF Score: 63/100

Uniqure NV Research & Development Day - Corporate Call Transcript

Jun 22, 2021 / 12:30PM GMT
Release Date Price: $30.04 (-7.74%)
Maria E. Cantor
uniQure N.V. - Chief Communications Officer

Good morning, everyone, and welcome to uniQure's Virtual Research and Development Day. I'm Maria Cantor, Chief Communications Officer at uniQure. We appreciate you taking time to be with us today.

Before we get started, please note that we'll be making a number of forward-looking statements this morning. We suggest that you take a moment to review this slide which contains our forward-looking statements. These statements involve risks and uncertainties, many of which are beyond uniQure's control, and actual results could differ materially from those that are in these statements. For a detailed description of these risks and uncertainties, we encourage you to review the company's most recent Form 10-Q filed with the Securities and Exchange Commission as well as the company's other SEC filings.

Regarding our agenda this morning, we will begin by reflecting on uniQure's long history of leadership in gene therapy and presenting our vision and strategy for the company over the next several years. We'll provide a program update on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot